-- Q4 2022 revenue projected to range from $275,000 to $285,000 ---- Full year 2022 revenue projected to range from…
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy Phase I/II trial will assess safety and efficacy…
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused…
Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular cancer patients Data reinforce the…
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered…
Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ETBEDMINSTER, N.J., Jan. 23, 2023 (GLOBE…
– State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts – – Awarded $1.9 million of state and local…
TORONTO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSX: VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) is pleased to announce…
Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies…
Castellum, Inc. Announces the Award of NAVAIR Contract for ALRE V2MMS Castellum, Inc. (NYSE-American: CTM) announces the award of the…